1.Utility of Treatment Pattern Analysis Using a Common Data Model: A Scoping Review
Eun-Gee PARK ; Min Jung KIM ; Jinseo KIM ; Kichul SHIN ; Borim RYU
Healthcare Informatics Research 2025;31(1):4-15
Objectives:
We aimed to derive observational research evidence on treatment patterns through a scoping review of common data model (CDM)-based publications.
Methods:
We searched the medical literature databases PubMed and EMBASE, as well as the Observational Health Data Sciences and Informatics (OHDSI) website, for papers published between January 1, 2010 and August 21, 2023 to identify research papers relevant to our topic.
Results:
Eighteen articles satisfied the inclusion criteria for this scoping review. We summarized study characteristics such as phenotypes, patient numbers, data periods, countries, Observational Medical Outcomes Partnership (OMOP) CDM databases, and definitions of index date and target cohort. Type 2 diabetes mellitus emerged as the most frequently studied disease, covered in five articles, followed by hypertension and depression, each addressed in four articles. Biguanides, with metformin as the primary drug, were the most commonly prescribed first-line treatments for type 2 diabetes mellitus. Most studies utilized sunburst plots to visualize treatment patterns, whereas two studies used Sankey plots. Various software tools were employed for treatment pattern analysis, including JavaScript, the open-source ATLAS by OHDSI, R code, and the R package “TreatmentPatterns.”
Conclusions
This study provides a comprehensive overview of research on treatment patterns using the CDM, highlighting the growing importance of OMOP CDM in enabling multinational observational network studies and advancing collaborative research in this field.
2.Utility of Treatment Pattern Analysis Using a Common Data Model: A Scoping Review
Eun-Gee PARK ; Min Jung KIM ; Jinseo KIM ; Kichul SHIN ; Borim RYU
Healthcare Informatics Research 2025;31(1):4-15
Objectives:
We aimed to derive observational research evidence on treatment patterns through a scoping review of common data model (CDM)-based publications.
Methods:
We searched the medical literature databases PubMed and EMBASE, as well as the Observational Health Data Sciences and Informatics (OHDSI) website, for papers published between January 1, 2010 and August 21, 2023 to identify research papers relevant to our topic.
Results:
Eighteen articles satisfied the inclusion criteria for this scoping review. We summarized study characteristics such as phenotypes, patient numbers, data periods, countries, Observational Medical Outcomes Partnership (OMOP) CDM databases, and definitions of index date and target cohort. Type 2 diabetes mellitus emerged as the most frequently studied disease, covered in five articles, followed by hypertension and depression, each addressed in four articles. Biguanides, with metformin as the primary drug, were the most commonly prescribed first-line treatments for type 2 diabetes mellitus. Most studies utilized sunburst plots to visualize treatment patterns, whereas two studies used Sankey plots. Various software tools were employed for treatment pattern analysis, including JavaScript, the open-source ATLAS by OHDSI, R code, and the R package “TreatmentPatterns.”
Conclusions
This study provides a comprehensive overview of research on treatment patterns using the CDM, highlighting the growing importance of OMOP CDM in enabling multinational observational network studies and advancing collaborative research in this field.
3.Utility of Treatment Pattern Analysis Using a Common Data Model: A Scoping Review
Eun-Gee PARK ; Min Jung KIM ; Jinseo KIM ; Kichul SHIN ; Borim RYU
Healthcare Informatics Research 2025;31(1):4-15
Objectives:
We aimed to derive observational research evidence on treatment patterns through a scoping review of common data model (CDM)-based publications.
Methods:
We searched the medical literature databases PubMed and EMBASE, as well as the Observational Health Data Sciences and Informatics (OHDSI) website, for papers published between January 1, 2010 and August 21, 2023 to identify research papers relevant to our topic.
Results:
Eighteen articles satisfied the inclusion criteria for this scoping review. We summarized study characteristics such as phenotypes, patient numbers, data periods, countries, Observational Medical Outcomes Partnership (OMOP) CDM databases, and definitions of index date and target cohort. Type 2 diabetes mellitus emerged as the most frequently studied disease, covered in five articles, followed by hypertension and depression, each addressed in four articles. Biguanides, with metformin as the primary drug, were the most commonly prescribed first-line treatments for type 2 diabetes mellitus. Most studies utilized sunburst plots to visualize treatment patterns, whereas two studies used Sankey plots. Various software tools were employed for treatment pattern analysis, including JavaScript, the open-source ATLAS by OHDSI, R code, and the R package “TreatmentPatterns.”
Conclusions
This study provides a comprehensive overview of research on treatment patterns using the CDM, highlighting the growing importance of OMOP CDM in enabling multinational observational network studies and advancing collaborative research in this field.
8.The Risk of COVID-19 and Its Outcomes in Korean Patients With Gout: A Multicenter, Retrospective, Observational Study
Min Jung KIM ; Borim RYU ; Eun-Gee PARK ; Siyeon YI ; Kwangsoo KIM ; Jun Won PARK ; Kichul SHIN
Journal of Korean Medical Science 2024;39(4):e37-
This retrospective cohort study aimed to compare coronavirus disease 2019 (COVID-19)-related clinical outcomes between patients with and without gout. Electronic health recordbased data from two centers (Seoul National University Hospital [SNUH] and Boramae Medical Center [BMC]), from January 2021 to April 2022, were mapped to a common data model. Patients with and without gout were matched using a large-scale propensityscore algorithm based on population-level estimation methods. At the SNUH, the risk for COVID-19 diagnosis was not significantly different between patients with and without gout (hazard ratio [HR], 1.07; 95% confidence interval [CI], 0.59–1.84). Within 30 days after COVID-19 diagnosis, no significant difference was observed in terms of hospitalization (HR, 0.57; 95% CI, 0.03–3.90), severe outcomes (HR, 2.90; 95% CI, 0.54–13.71), or mortality (HR, 1.35; 95% CI, 0.06–16.24). Similar results were obtained from the BMC database, suggesting that gout does not increase the risk for COVID-19 diagnosis or severe outcomes.
9.Corrigendum: Korean treatment recommendations for patients with axial spondyloarthritis
Mi Ryoung SEO ; Jina YEO ; Jun Won PARK ; Yeon-Ah LEE ; Ju Ho LEE ; Eun Ha KANG ; Seon Mi JI ; Seong-Ryul KWON ; Seong-Kyu KIM ; Tae-Jong KIM ; Tae-Hwan KIM ; Hye Won KIM ; Min-Chan PARK ; Kichul SHIN ; Sang-Hoon LEE ; Eun Young LEE ; Hoon Suk CHA ; Seung Cheol SHIM ; Youngim YOON ; Seung Ho LEE ; Jun Hong LIM ; Han Joo BAEK ;
Journal of Rheumatic Diseases 2024;31(1):62-63
10.Corrigendum: Treatment sequence after initiating biologic therapy for patients with rheumatoid arthritis in Korea:a nationwide retrospective cohort study
Min Jung KIM ; Jun Won PARK ; Sun-Kyung LEE ; Yumi JANG ; Soyoung KIM ; Matthias STOELZEL ; Jonathan Lumen CHUA ; Kichul SHIN
Journal of Rheumatic Diseases 2024;31(4):263-263

Result Analysis
Print
Save
E-mail